Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
4D Molecular Therapeutics, Inc. Market Cap
From what 12 stock analysts predict, the share price for 4D Molecular Therapeutics, Inc. (FDMT) might increase by 530.34% in the next year. This is based on a 12-month average estimation for FDMT. Price targets go from $8 to $82. The majority of stock analysts believe FDMT is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
4D Molecular Therapeutics, Inc. has a total of 12 Wall St Analyst ratings. There are 10 buy ratings, 1 ratings, and 1 sell ratings. Since most analysts have a buy consensus rating, the expectation is that 4D Molecular Therapeutics, Inc. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of FDMT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Judah Frommer Morgan Stanley | Underweight | $8 | Initiates | Nov 21, 2024 |
| Luca Issi RBC Capital | Outperform | $39 | Maintains | Nov 14, 2024 |
| Geulah Livshits Chardan Capital | Buy | $39 | Maintains | Nov 14, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $36 | Reiterates | Nov 14, 2024 |
| Josh Schimmer Cantor Fitzgerald | Neutral | Downgrade | Sep 23, 2024 | |
| Matthew Caufield HC Wainwright & Co. | Buy | $36 | Reiterates | Sep 19, 2024 |
| Geulah Livshits Chardan Capital | Buy | $39 | Maintains | Sep 19, 2024 |
| Mani Foroohar Leerink Partners | Outperform | $36 | Reiterates | Sep 19, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | Reiterates | Sep 9, 2024 | |
| Matthew Caufield HC Wainwright & Co. | Buy | $36 | Reiterates | Aug 9, 2024 |
| Luca Issi RBC Capital | Outperform | $40 | Reiterates | Jul 22, 2024 |
| Kostas Biliouris BMO Capital | Outperform | $40 | Maintains | Jul 18, 2024 |
| Geulah Livshits Chardan Capital | Buy | $38 | Maintains | Jul 17, 2024 |
| Luca Issi RBC Capital | Outperform | $40 | Reiterates | Jun 26, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $36 | Reiterates | Jun 7, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $36 | Reiterates | May 13, 2024 |
| Gena Wang Barclays | Overweight | $45 | Initiates | Apr 15, 2024 |
| Luca Issi RBC Capital | Outperform | $40 | Maintains | Apr 15, 2024 |
| Nalin Tejavibulya Jefferies | Buy | $58 | Maintains | Apr 1, 2024 |
| Kostas Biliouris BMO Capital | Outperform | $63 | Maintains | Apr 1, 2024 |
When did it IPO
2020
Staff Count
147
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. David H. Kirn M.D.
Market Cap
$362.4M
In 2023, FDMT generated $20.7M in revenue, which was a increase of 562.29% from the previous year. This can be seen as a signal that FDMT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - 4D Molecular Therapeutics (Nasdaq: FDMT) reported its Q3 2024 financial results and shared operational highlights and future milestones on November 13, 2024.
Why It Matters - 4D Molecular Therapeutics' Q3 2024 results and milestones can influence stock performance, signaling potential growth and investor confidence in its genetic medicine pipeline.
Wed, 13 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - 4D Molecular Therapeutics reported a quarterly loss of $0.79 per share, exceeding the expected loss of $0.67, compared to a loss of $0.24 per share a year prior.
Why It Matters - 4D Molecular Therapeutics' larger-than-expected quarterly loss signals worsening financial health, potentially impacting investor confidence and stock performance.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating 4D Molecular Therapeutics (NASDAQ:FDMT) for potential securities law violations, specifically regarding false or misleading statements to investors.
Why It Matters - The investigation into 4D Molecular Therapeutics for potential securities law violations could impact stock value, investor confidence, and future legal liabilities.
Sat, 02 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating 4D Molecular Therapeutics (NASDAQ:FDMT) for potential securities law violations, including false statements and undisclosed information affecting investors.
Why It Matters - The investigation into 4D Molecular Therapeutics for potential securities law violations could lead to legal risks, affecting its stock price and investor confidence.
Sun, 03 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating 4D Molecular Therapeutics (NASDAQ:FDMT) for potential securities law violations, including false statements and nondisclosure of important information.
Why It Matters - The investigation into 4D Molecular Therapeutics for potential securities law violations may signal risks for shareholders, impacting stock performance and investor confidence.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating 4D Molecular Therapeutics (NASDAQ:FDMT) for potential securities law violations related to misleading statements made to investors.
Why It Matters - The investigation into 4D Molecular Therapeutics for potential securities law violations could signal risks for investors, impacting stock performance and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
